Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Foscarbidopa/foslevadopa - Abbvie

Next Previous
Drug Profile

Foscarbidopa/foslevadopa - Abbvie

Alternative Names: ABBV 951; foscarbidopa/foslevodopa; Foslevodopa/foscarbidopa; Levodopa/carbidopa prodrug; PRODUODOPA; VYALEV; Vyalev

Latest Information Update: 19 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Class Antiparkinsonians; Aromatic amino acids; Carboxylic acids; Catecholamines; Hydrazines; Phosphates; Small molecules
  • Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 05 Apr 2025 Updated efficacy and adverse events data from a phase III trial in Parkinson's disease presented at 77th Annual Meeting of the American Academy of Neurology 2025 (AAN-2025)
  • 17 Oct 2024 Registered for Parkinson's disease in USA (SC)
  • 25 Jun 2024 Abbvie receives complete response letter from the FDA for foscarbidopa/foslevodopa in Parkinson's disease based on observations that were identified during inspection of a third-party manufacturer listed in the New Drug Application (NDA)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top